Pbi-Shrna™ Ews/Fli1 Type 1 Lipoplex
Rare Diseases
Gradalis, Inc.nucleic_acidPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Rare Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Burosumab Bicetre Hospital | Phase 4 | BB |
Irinotecan Gradalis, Inc. | Phase 3 | B |
FILGRASTIM Hospices Civils de Lyon | Phase 2/3 | B |
Crofelemer Napo Pharmaceuticals, Inc. | Phase 2/3 | B |
GEMOGENOVATUCEL-T Gradalis, Inc. | Phase 3 | B |
View all 11 →
Same molecule, other indications
Pbi-Shrna™ Ews/Fli1 Type 1 Lipoplex is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →